#United States #San Jose #BPH Treatment #Resurge Therapeutics #IPDE Platform

Positive Clinical Outcomes from Resurge Therapeutics

Resurge Therapeutics, known for its pioneering work in urology, has recently shared promising clinical findings related to its novel treatment for Benign Prostatic Hyperplasia (BPH). The results, which will be highlighted at the upcoming American Urological Association (AUA) Annual Meeting in Washington, D.C., mark a significant milestone in addressing the challenges faced by men suffering from lower urinary tract symptoms (LUTS).

Overview of the Research

The focus of the studies was the IntraProstatic Drug Elution (IPDE) therapy, an innovative, office-based drug treatment designed for effective prostate remodeling. With the goal of delivering long-lasting symptom relief, the therapy shows potential as a leading localized treatment for BPH. Two studies assessing the therapy were conducted using paclitaxel-eluting bioabsorbable implants, delivered through both transperineal and transrectal approaches.

Notable Results from the Studies

The clinical evaluation revealed significant improvements in both symptom severity and urinary flow rates, paired with a robust safety profile. Key findings include:

• - In the first study, a transperineal dose escalation trial with 20 participants demonstrated an impressive average International Prostate Symptom Score (IPSS) improvement of 15 points one year following a single treatment. The maximum urinary flow rate (Qmax) increased by approximately 4 mL/s, with around 80% of patients experiencing clinically significant symptom relief. Importantly, there were no serious adverse events or systemic drug toxicity reported.
• - The transrectal feasibility study involved 11 participants and showed similar results, with an average IPSS improvement of 15 points observable as early as one month after treatment and maintained through six months. Participants also saw a Qmax increase of 4.1 mL/s and a 23% reduction in prostate volume by the six-month mark, again with no serious adverse events.

Patient Acceptance and Tolerability

Across both clinical trials, patients reported minimal discomfort post-treatment, with average pain scores on a visual analogue scale being 1 out of 10. The absence of complications like erectile dysfunction emphasizes the therapy's potential in transforming prostate treatment practices into a more comfortable experience for patients.

Implications for BPH Treatment

“This continued evidence reinforces the potential of our IPDE platform as a one-time localized therapy capable of tackling the limitations of chronic oral medications and invasive surgeries,” remarked Dr. Shahram Gholami, co-founder of Resurge Therapeutics. Given that BPH affects around 40 million men in the U.S., with many relying on less effective oral medications, the IPDE therapy seems well-positioned to fill a vital gap in patient care.

Future Directions

Resurge Therapeutics plans to further advance its promising IPDE therapy into larger, randomized, double-blind, placebo-controlled clinical trials both in the U.S. and internationally. The company is also actively collaborating with regulatory authorities to facilitate the next stages of development.

The potential U.S. market opportunity for the IPDE therapy could exceed $5 billion annually, a significant business prospect that underlines the necessity for better BPH treatment solutions. If validated through broader clinical trials, the IPDE platform could offer a durable and innovative solution for BPH, altering the treatment paradigm to benefit millions of men.

As Resurge Therapeutics progresses, it stands at the forefront of urological innovations, striving to improve the quality of life for those affected by BPH through breakthroughs in localized drug therapy.

About Resurge Therapeutics

Founded by experts in the field, Resurge Therapeutics is dedicated to developing localized drug delivery methods for urological conditions. With continued advancements in their therapeutic platforms, the company aims to revolutionize treatment strategies for urological diseases.